よむ、つかう、まなぶ。
04資料2-1_森野委員提出資料（おたふくかぜワクチンファクトシート第２版） (54 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_73851.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第34回 6／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
167.
Mäkelä A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella
vaccination. Pediatrics 2002; 110(5): 957–63.
168.
Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella--
vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and
control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep 1998; 47(Rr-8): 1–57.
169.
Patja A, Mäkinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-
mumps-rubella vaccination. Pediatrics 2001; 107(2): E27.
170.
Hamad Saied M, van Straalen JW, de Roock S, et al. Safety of Measles-Mumps-Rubella
booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study. Vaccine
2023; 41(18): 2976–81.
171.
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-
old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK
MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Hum Vaccin
Immunother 2019; 15(4): 786–99.
172.
Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M. Immunogenicity and
safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered
concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Vaccine 2015;
33(20): 2379–86.
173.
Klein NP, Weston WM, Kuriyakose S, et al. An open-label, randomized, multi-center study of
the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or
without varicella vaccine in healthy pre-school age children. Vaccine 2012; 30(3): 668–74.
54
Mäkelä A, Nuorti JP, Peltola H. Neurologic disorders after measles-mumps-rubella
vaccination. Pediatrics 2002; 110(5): 957–63.
168.
Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella--
vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and
control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR Recomm Rep 1998; 47(Rr-8): 1–57.
169.
Patja A, Mäkinen-Kiljunen S, Davidkin I, Paunio M, Peltola H. Allergic reactions to measles-
mumps-rubella vaccination. Pediatrics 2001; 107(2): E27.
170.
Hamad Saied M, van Straalen JW, de Roock S, et al. Safety of Measles-Mumps-Rubella
booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study. Vaccine
2023; 41(18): 2976–81.
171.
A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-
old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK
MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Hum Vaccin
Immunother 2019; 15(4): 786–99.
172.
Deichmann KA, Ferrera G, Tran C, Thomas S, Eymin C, Baudin M. Immunogenicity and
safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered
concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Vaccine 2015;
33(20): 2379–86.
173.
Klein NP, Weston WM, Kuriyakose S, et al. An open-label, randomized, multi-center study of
the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or
without varicella vaccine in healthy pre-school age children. Vaccine 2012; 30(3): 668–74.
54